The beta blocker Bystolic (nebivolol), a once-daily medication that can be used alone or in combination with other hypertension treatments, has received FDA marketing clearance.
In extensive clinical trials involving more than 2,000 patients, Bystolic demonstrated significant reductions in sitting diastolic and systolic BP in a general hypertensive population. Bystolic’s common side effects reported in clinical trials were headache, fatigue, dizziness and diarrhea. Mylan Bertek Pharmaceuticals Inc., of Research Triangle Park, N.C., is the sponsor of Bystolic. New York City-based Forest Laboratories, Inc. holds sales and marketing rights to the drug.